Nourhane J Obeid1, Khaled H Soukarieh1, Jessy G Fadel2, Rayyan M Wazzi-Mkahal3, Marianne A Alwan3, Jessica J Fakhir4, Paul W Rassam1, Najat I Fares3 and Mona H Hallak1*
1Department of Internal Medicine, Division of Gastroenterology, Saint Georges Hospital University Medical Center, University of Balamand, Beirut, Lebanon 2Department of Internal Medicine, Saint Georges Hospital University Medical Center, University of Balamand, Beirut, Lebanon 3Department of Internal Medicine, Division of Nephrology, Saint Georges Hospital University Medical Center, University of Balamand, Beirut, Lebanon 4Department of Pharmacy, Saint Georges Hospital University Medical Center, Lebanese University, Beirut, Lebanon
*Corresponding Author: Mona H Hallak, Department of Internal Medicine, Division of Gastroenterology, Saint Georges Hospital University Medical Center, University of Balamand, Beirut, Lebanon.
Received: October 17, 2022; Published: October 25, 2022
Background: Hepatitis A is a common viral infection worldwide that is transmitted via the fecal-oral route. Since the introduction of an efficient vaccine, the incidence of infection has decreased but the number of cases has risen due to widespread community outbreaks among unimmunized individuals. Classic symptoms include fever, malaise, dark urine and jaundice, and are more common in older children and adults. People are often most infectious 14 days prior to and seven days following the onset of jaundice.
Case Report: We will discuss the case of a young male patient, diagnosed with acute hepatitis A leading to fulminant hepatitis refractory to conventional therapy and the development of subsequent kidney injury. The medical treatment through the course of hospitalization was challenging and included the use of L-ornithine-L-aspartate and prolonged intermittent hemodialysis, leading to a remarkable outcome.
Conclusion: Hepatitis A is usually self-limited and vaccine-preventable; supportive care is often sufficient for treatment, and chronic infection or chronic liver disease rarely develops. However, fulminant hepatitis, although rare, can be very challenging to manage as in the case of our patient.
Keywords: Fulminant Hepatitis; Hepatitis A; L-ornithine-L-aspartate; Intermittent Renal Replacement Therapy; Continuous Renal Replacement Therapy; A Case Report
Citation: Mona H Hallak., et al. “L-ornithine L-aspartate and Intermittent Renal Replacement Therapy in Fulminant Hepatitis A: A Case Report". Acta Scientific Gastrointestinal Disorders 5.11 (2022): 41-46.
Copyright: © 2022 Mona H Hallak., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.